Get the Stockscreener App
0.7696
0.70%
-0.0054
After Hours:
.78
0.0104
+1.35%
Tenaya Therapeutics Inc stock is traded at $0.7696, with a volume of 1.11M.
It is down -0.70% in the last 24 hours and up +7.26% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.775
Open:
$0.7556
24h Volume:
1.11M
Relative Volume:
0.32
Market Cap:
$167.00M
Revenue:
-
Net Income/Loss:
$-83.01M
P/E Ratio:
-1.6333
EPS:
-0.4712
Net Cash Flow:
$-64.63M
1W Performance:
-5.94%
1M Performance:
+7.26%
6M Performance:
+10.29%
1Y Performance:
-7.63%
1-Day Range:
$0.751
$0.82
1-Week Range:
$0.75
$0.8333
52-Week Range:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7696 | 168.17M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
TNYA|Tenaya Therapeutics Inc|Price:0.769|Chg%:-0.006 - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Tenaya Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNYA - TradingView
Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenaya Therapeutics Inc|Price:0.775|Chg%:+0.002 - TradingKey
Tenaya Therapeutics Inc (TNYA) Institutional Confidence - TradingKey
Tenaya Therapeutics Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances Heart Disease Pipeline - dars.gov.et
Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: EPS Slightly Misses Estimates, Stock Declines as Pre-Revenue Biotech Continues Pipeline DevelopmentOne-Time Gain Impact - dars.gov.et
Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price - Stock Titan
Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report - Stock Titan
Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: Slight EPS Miss Overshadowed by Pipeline ProgressSurprise Factor Analysis - dars.gov.et
Tenaya Therapeutics, Inc. Podcast | TNYA Podcasts & Related Content - finance.biggo.com
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA) - The Globe and Mail
Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
TNYATenaya Therapeutics Inc Options - Finviz
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO - Stock Titan
Tenaya Therapeutics Ends Manufacturing Center Lease, Shifts Strategy - TipRanks
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Investing News Network
Tenaya Therapeutics appoints Eric Hyllengren as CFO By Investing.com - Investing.com Australia
Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026 - marketscreener.com
Tenaya Therapeutics Appoints New Chief Financial Officer - TipRanks
Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA) - Stock Titan
Tenaya Therapeutics appoints Eric Hyllengren as CFO - Investing.com
Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Moomoo
Price to book forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to sales forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to earnings forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Enterprise value to revenue forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenaya Therapeutics Inc (TNYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenaya Therapeutics Q1 2026 Earnings: EPS Slightly Misses Estimates as Biotech Advances Heart Disease Pipeline - dars.gov.et
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):